Monoclonal antibodies are the way out of the Covid-19 pandemic
Whether they are acting as a therapeutic or preventive treatment, monoclonal antibodies can allow us to help contain the virus, where we might see the light at the end of the tunnel.
Whether they are acting as a therapeutic or preventive treatment, monoclonal antibodies can allow us to help contain the virus, where we might see the light at the end of the tunnel.
CVS Health’s infusion business will participate in a pilot to administer a recently authorized monoclonal antibody treatment to prevent patients from getting seriously ill with Covid-19. But data about the treatment, bamlanivimab, is mixed, and supply is limited.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The drugmaker said Friday that it would partner with Shanghai-based I-Mab on the development of lemzoparlimab, a drug that targets CD47. The antigen target, also known as the "don't eat me" signal, is a growing area of immunotherapy, as illustrated by Gilead's $4.9 billion buyout of Forty Seven in March.
The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and health authorities in the U.S., is enrolling up to 48 healthy volunteers in the U.K. AstraZeneca's double-antibody approach is similar to that of Regeneron and Roche with their drug, REGN-COV2.
The company has a "unique" approach to treating Alzheimer's, CEO Arnon Rosenthal says - taking an immunotherapy approach to neurodegenerative disease.
The company is raising $50 million, on top of some $43 million it's raised this year, according to regulatory filings.
This acquisition is a logical fit for Ligand, as OMT will add a slew of monoclonal antibody therapeutics to its small molecule-dominant pipeline.
New Jersey biosimilar maker Oncobiologics just raised $31 million. It's developing biosimilars for 11 monoclonal antibody drugs that will soon go off-patent, such as Humira, Avastin and Herceptin.
Pfizer is launching a new, competitive grant program that solicits research projects on the gene PCSK9’s role in cardiovascular disease. It marks yet another step in big pharma’s goal to directly plumb academia for insights on their own drug targets. The grant program, through Pfizer’s Aspire initiative (Advancing Science through Pfizer Investigator Research Exchange), will fund grants up […]
A Bay Area startup is harnessing the haute monoclonal antibody technology to develop treatment for psoriasis, cancers and inflammatory disease, and is likely about to kick off some serious late-stage efficacy trials. AbGenomics is in the midst of a $24.5 million fundraising round, according to regulatory filings, and has raised $13.2 million to date. The company […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Cambridge startup Siamab Therapeutics has changed up its direction, now developing monoclonal antibodies to hinder the progressive growth of tumors. The company just received another $2 million in funding, largely from angel investors, rounding out a $6 million Series B that began last year. On top of that, it just changed its name from Sialix to Siamab Therapeutics, representing the company’s […]